Citigroup
IKT icon

Citigroup’s Inhibikase Therapeutics IKT Stock Holding History

Citigroup’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$114K Buy
56,090
+51,058
+1,015% +$91.4K ﹤0.01% 4603
2026
Q1 		$8.45K Buy
5,032
+1,746
+53% +$3.1K ﹤0.01% 5102
2025
Q4 		$6.74K Buy
3,286
+2,384
+264% +$3.79K ﹤0.01% 5171
2025
Q3 		$1.46K Sell
902
-19,491
-96% -$33.8K ﹤0.01% 5558
2025
Q2 		$39.8K Sell
20,393
-5,372
-21% -$10.5K ﹤0.01% 4881
2025
Q1 		$56.4K Sell
25,765
-51,335
-67% -$129K ﹤0.01% 4846
2024
Q4 		$251K Buy
+77,100
New +$192K ﹤0.01% 4273
2022
Q3 		– Sell
-83
Closed – – 6061
2022
Q2 		$0 Buy
+83
New +$490 ﹤0.01% 6419

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citigroup's IKT Position: Q2 2026 in Review

Citigroup increased its Inhibikase Therapeutics (IKT) stake by 1,015% in Q2 2026, buying an estimated $91.4K and bringing the position to 56,090 shares worth $114K. The position accounts for ﹤0.01% of the portfolio, ranked #4603.

Citigroup first reported a position in IKT in Q2 2022 and has held it in 8 quarters since. The position peaked at $251K in Q4 2024. 105 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Citigroup held 56,090 shares of Inhibikase Therapeutics worth $114K as of Q2 2026.
  • Citigroup bought 51,058 Inhibikase Therapeutics shares in Q2 2026, an estimated $91.4K.
  • Inhibikase Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4603 holding.
  • Citigroup first reported a position in Inhibikase Therapeutics in Q2 2022 and has held it in 8 quarters since.
  • Citigroup's Inhibikase Therapeutics position peaked at $251K in Q4 2024.
  • 105 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.